FDA sets November review date for J&J’s multiple myeloma CAR-T cilta-celJohnson & Johnson has secured a six-month FDA review for its multiple myeloma CAR-T therapy ciltacabtagene autoleucel (cilta-cel), Share XFDA sets November review date for J&J’s multiple myeloma CAR-T cilta-celhttps://pharmaphorum.com/news/fda-sets-november-review-date-for-jjs-multiple-myeloma-car-t-cilta-cel/
Janssen files its first CAR-T therapy cilta-cel in EuropeJohnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, Share XJanssen files its first CAR-T therapy cilta-cel in Europehttps://pharmaphorum.com/news/janssen-files-its-first-car-t-therapy-cilta-cel-in-europe/
BCMA Targeted Therapies SummitBuilt with thought leaders from Seattle Genetics, Precision Biosciences and Kite Pharma, the inaugural industry-focused BCMA Targeted Therapies Share XBCMA Targeted Therapies Summithttps://pharmaphorum.com/events/bcma-targeted-therapies-summit/
